Bloomberg News recently published a lengthy piece on how carcinogens are allegedly infiltrating the generic drug supply in the United States. The very next day, drug safety officials announced that they were investigating whether Zantac and its generic counterparts contain levels of the probable carcinogen N-Nitrosodimethylamine, or NDMA – the same chemical that was found in blood-pressure pills last year. Those pills were ultimately recalled, and those recalls are still expanding as we saw this week with Torrent Pharmaceuticals Ltd. Now Sanofi, having confirmed the presence of NDMA, has started to recall generic Zantac.
Now the same show is on replay.
Here are some of the key facts repeated in all the coverage, along with between-the-lines lessons manufacturers should be taking away from how this story is playing out:
Our experience tells us we’re far from the end of this story. More products and more companies will be impacted – whether they produce ranitidine or simply work with an overseas manufacturing facility. The real question: Are you are ready?
Stericycle Expert Solutions focuses on helping customers by providing proven, customer-centric, scalable services that protect people and brands, promote health and safeguard the environment.find out more
A much needed spotlight on challenges facing companies and the CPSC. Consumer groups like @kidsindanger will contin… https://t.co/kuXYoSe9Xh
If you’re ready to get started with our extensive suite of services then contact us today. We have a team of experts ready to assist you!Contact Us today